Mol Neurobiol
Molecular Neurobiology
0893-7648
1559-1182
Humana Press Inc
New York


2039847
17917109
29
10.1007/s12035-007-0029-7
Article


Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer’s Disease

Wilhelmus
Micha M. M.

1
2

de Waal
Robert M. W.

2

Verbeek
Marcel M.

+31-24-3614567
+31-24-3668754
m.verbeek@cukz.umcn.nl

1

1
Department of Neurology and Alzheimer Centre, Radboud University Nijmegen Medical Centre, 830 LKN, P.O. Box 9101, 6500 HB Nijmegen, Netherlands 
2
Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 

6
7
2007

6
2007

35
3
203
216
28
6
2006

10
11
2006


© Humana Press Inc. 2007

The pathologic lesions of Alzheimer’s disease (AD) are characterized by accumulation of protein aggregates consisting of intracellular or extracellular misfolded proteins. The amyloid-β (Aβ) protein accumulates extracellularly in senile plaques and cerebral amyloid angiopathy, whereas the hyperphosphorylated tau protein accumulates intracellularly as neurofibrillary tangles. “Professional chaperones”, such as the heat shock protein family, have a function in the prevention of protein misfolding and subsequent aggregation. “Amateur” chaperones, such as apolipoproteins and heparan sulfate proteoglycans, bind amyloidogenic proteins and may affect their aggregation process. Professional and amateur chaperones not only colocalize with the pathological lesions of AD, but may also be involved in conformational changes of Aβ, and in the clearance of Aβ from the brain via phagocytosis or active transport across the blood–brain barrier. Thus, both professional and amateur chaperones may be involved in the aggregation, accumulation, persistence, and clearance of Aβ and tau and in other Aβ-associated reactions such as inflammation associated with AD lesions, and may, therefore, serve as potential targets for therapeutic intervention.

Keywords
Alzheimer’s disease
Amyloid
Heat shock proteins
Heparan sulfate proteoglycans
Apolipoproteins
Amyloid beta-protein
Chaperones

issue-copyright-statement
© Humana Press 2007




Introduction
1
2
3
2
1-40
1-42
4
6
7
]. In contrast to normal brain, the cerebral Aβ balance is disturbed in AD brains, resulting in accumulation and aggregation of Aβ.
8
9
10
11
13
]. Activation of these cell types results in increased secretion of pro-inflammatory cytokines as part of a neuro-inflammatory reaction.
Chaperones can be defined as proteins that: (1) have a role in the intracellular handling of misfolded proteins, (2) induce conformational changes of proteins, (3) act as transporter of proteins. “Professional” chaperones, such as the heat shock protein family (Hsp), are defined as proteins that have a specific function in facilitating normal folding of proteins and intracellular handling of misfolded proteins. Members of the Hsp family recognize misfolded proteins and transport them to the proteasome for degradation. Therefore, this protein family acts as the first line of defense against toxicity induced by misfolded proteins such as Aβ and tau. In contrast to professional chaperones, “amateur” chaperones can be defined as proteins that bind to other proteins and induce conformational changes or, alternatively, serve as transporter proteins. Examples of putative amateur chaperones are apolipoprotein E (ApoE), heparan sulfate proteoglycans (HSPGs), and complement factors such as C1q. They have, in contrast to the professional chaperones, primarly an extracellular function. In this paper, we will review the role of both amateur and professional chaperones in the pathogenesis of AD.

Aβ-Binding Proteins in Extracellular Interaction with Aβ
Apolipoproteins
The apolipoprotein family consists of proteins that conjugate with lipids to form different classes of lipoprotein particles. In human brain, several members of this protein family are expressed, such as apolipoprotein E (ApoE), apolipoprotein J (ApoJ), and apolipoprotein D (apoD).
14
18
19
20
].
21
24
25
26
27
28
29
30
29
18
31
33
].
31
32
34
35
36
37
38
39
40
36
]. Although these Tg mice studies seem contradictional, ApoE clearly affects conformational changes of Aβ and functions as an Aβ-transporter protein.
25
41
42
43
45
].
5
6
46
47
50
51
52
]. Transgenic mice expressing the ApoE4 protein isoform show a greater NO production than mice expressing the ApoE3 protein isoform. These data indicate that ApoE4 has a less efficient anti-inflammatory affect, and thus, may accelerate the development of AD.
53
54
56
57
58
59
].
In conclusion, ApoE and ApoJ can be regarded as amateur chaperones that regulate Aβ aggregation in vitro. By accelerating the Aβ aggregation process towards mature fibril formation, (human) ApoE prevents formation of toxic Aβ intermediates such as oligomers and protofibrils, and thus, may have a protective function towards development of AD. Moreover, ApoE protects against the development of AD by suppressing the inflammatory reactions associated with AD lesions. Besides its role in inducing conformational changes in Aβ, ApoE facilitates Aβ clearance from brain by serving as a transporter molecule of Aβ, which will be discussed in paragraph 4.

Heparan Sulfate Proteoglycans
N
60
61
60
62
].
63
65
65
67
68
69
69
72
].
73
70
74
76
77
78
79
80
].
81
82
83
]. The efficacy of one of these compounds is currently being tested in a human phase III trial.
84
85
86
].
61
].

Complement Factors
46
87
89
90
91
87
92
93
94
95
96
]. Thus, an activated complement system is a general feature observed in AD. However, the contribution of complement to the pathogenesis of AD is controversial.
97
97
98
100
].
12
90
101
102
103
104
]. This suggests that microglia may get triggered by both Aβ- and SP-associated factors such as C1q, which results in the secretion of pro-inflammatory cytokines and Aβ, both accelerating neurodegeneration.
Although none of the complement factors directly regulate conformational changes of Aβ, complement activation as a whole plays a role in the Aβ aggregation in vivo. Therefore, complement factors might act as amateur chaperones, although their exact role in Aβ aggregation remains to be elucidated.

Professional Chaperones
105
105
106
107
1
Fig. 1
Hsp
sHsps
) in recognition and refolding of unfolded and misfolded proteins. Unfolded or misfolded proteins are recognized by Hsps and sHsps. Together with these unfolded or misfolded proteins, Hsps and sHsps form a complex. In addition, Hsps recover unfolded or misfolded proteins back to their native form using ATP. If unfolded or misfolded protein are not recognized by the Hsp/sHsps, these unfolded or misfolded proteins are capable of forming aggregates




Small Heat Shock Proteins
108
109
110
]. Although sHsps are predominantly expressed in muscle cells, several family members are also found in human brain.
111
114
115
116
111
117
119
120
121
116
117
122
].
113
123
126
127
128
]. Thus, the state of misfolded protein recognition and repair systems, such as the (s)Hsp system, might be of great importance in the development of neurodegenerative diseases.


Miscellaneous Proteins
1
2
129
132
133
135
134
135
136
137
138
139
140
141
142
104
]. These observations further strengthen the above-noted suggestion that not only Aβ, but also several Aβ-binding proteins, are capable of activating the complement system, and thus, contribute to neuroinflammation in AD. In addition, both α2M and ACT, in contrast to SAP, can be regarded as amateur chaperones, as they regulate conformational changes of Aβ.
143
144
145
144
146
]. Although tPA has no effect on conformational changes of Aβ, it might play a role in the clearance of Aβ from the brain (paragraph 4].
147
148
149
150
151
].
152
153
154
155
156
].
In summary, several proteins are associated with Aβ aggregates in the AD brain and contribute to the aggregation of Aβ and should, therefore, be considered as amateur chaperones. In addition, they might play a role in triggering inflammation.


Aβ-Binding Proteins and Intracellular Interactions with Aβ
157
159
160
161
162
160
].
163
164
]. However, whether these intracellular Aβ-binding proteins affect aggregation of Aβ within the cells remains unknown. Therefore, both these proteins cannot, for the time being, be defined as amateur chaperones of Aβ.
165
].
166
167
132
168
171
172
173
174
1
Table 1
Summary of the expression of chaperones in AD brains and their interaction and effects on Aβ and tau

 

SP/CAA
NFT
Direct interaction
Effects on Aβ or tau in general


Apolipoproteins

 ApoE
+
+
Aβ/tau
↑ Fibrillar Aβ /↓ hyperph. Tau

 ApoJ
+
?
Aβ
↓ Aβ aggregation

HSPGs

 Perlecan
±
±
Aβ
HSPGs:

 Agrin
+
−
Aβ
↓ Proteolytic breakdown Aβ

 Glypican 1
+
−
?
↑ Non-fibrillar → fibrillar Aβ

 Syndecan 1–3
+
−
?
↑ Phosphorylation tau

 Collagen XVIII
+
−
?


 GAGs
+
+
Aβ/tau


Complement factors

 Hageman Factor
+
+
?
Aβ activates complement in AD

 C1q
+
+
Aβ
C3 ↓ Aβ deposition

 C3/C4
+
+
Aβ


 C5-9
+
+
?


Heat shock proteins

 Hsp90
+
?
Tau
↓ Tau aggregation

 Hsp70
+
?
Aβ/tau
↓ Tau aggregation

Small Hsps

 αB-crystallin
−
−
Aβ
↓ Aβ fibril formation

 Hsp27
−
±
Aβ/tau
↓ Aβ fibril formation

 Hsp20
+
−
Aβ
↓ Aβ fibril formation

 HspB2/B3
+
+
–
No effect

 HspB8
+
−
Aβ
↓ Aβ fibril formation

Acute phase proteins

1
-antichymotrypsin
+
−
Aβ
↑ Aβ fibrillization

2
-macroglobulin
+
−
Aβ


 serum amyloid P
+
+
Aβ
↑ Aβ fibrillization

Miscellaneous compounds

 tPA
−
−
Aβ
↓ Aβ fibril formation

 Gelsolin
−
−
Aβ
↑ Aβ fibrillization



Expression of chaperones in a specific lesion is illustrated as follows: present (+), by conflicting reports (±), absence (−), and unknown (?); ↓ = inhibition or down-regulation, ↑ = induction or up-regulation
SP
CAA
NFT
HSPGs
Aβ
Hsp
Apo
SAP
tPA
GAGs
LDLR
LRP-1
BBB
 blood–brain barrier




Aβ-Binding Proteins and Aβ Clearance
Aβ-binding proteins, amateur chaperones, play a role in the clearance of Aβ from brain by functioning as a transporter molecule. Two major pathways govern Aβ clearance. By the first pathway, Aβ is removed from brain to blood via active transport across the BBB. This active transport is performed by specialized transporters, so-called “Aβ-receptors”, expressed by endothelial cells. Second, Aβ is removed from brain via phagocytosis by both microglial cells and astrocytes. In both pathways, interaction of Aβ with cell surface Aβ-receptors is crucial; therefore, the expression levels of Aβ-binding proteins might contribute to Aβ clearance by regulating its binding with Aβ receptors.
4
175
10
176
177
178
179
179
7
139
].
180
182
183
184
184
181
184
].
185
187
132
188
189
40
146
]. Thus, as Aβ-chaperones contribute to activation of the complement system or activation of microglial cells and astrocytes, these proteins might contribute to the clearance of Aβ from the brain via phagocytosis.

Concluding Remarks
2
Fig. 2
Aβ
1
2
-macroglobulin (α2M), whereas complement factors stimulate phagocytosis-mediated clearance of Aβ by activated microglia and astrocytes




184
].
Overexpression of professional chaperones, such as the Hsps, to prevent aggregation of misfolded proteins will have to be evaluated carefully, as they also interact with other chaperones and are dependent on this interaction to fulfill some of their functions. This strategy may therefore result in instability of the cell-stress mechanism, which may cause the system to collapse. A solution may be found in the overexpression of several chaperones, which may be required to achieve an impact on the progression of the disease.
121
]. Furthermore, Hsps are most likely to be involved in early development of neurodegenerative diseases, given their natural function. Yet, the role of this protein family in maturation of the neurodegenerative lesions remains to be elucidated.
In conclusion, studying the role of chaperones, both professional and amateur, in the pathophysiology of AD will provide us with a better understanding of the mechanisms underlying the formation and accumulation of toxic aggregates in AD, which, eventually, will lead to the design of more effective therapeutic strategies.


This work was supported by grants from the “Internationale Stichting Alzheimer Onderzoek” (ISAO, grants 01506 and 03517), Zon-MW Innovational Research (number 917.46.331, “Vidi program”) and the “Hersenstichting Nederland” (number 11F03(2)11 and 14F06.18). We would like to thank Wilbert Boelens for helpful discussions.

References
1.
Selkoe
DJ


The molecular pathology of Alzheimer’s disease
Neuron
1991
6
487
498

1673054


2.
Glenner
GG

Wong
CW


Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Biochem Biophys Res Commun
1984
120
885
890

6375662


3.
Lee
VM

Balin
BJ

Otvos
L

Trojanowski
JQ


A68: a major subunit of paired helical filaments and derivatized forms of normal tau
Science
1991
251
675
678

1899488


4.
Zlokovic
BV


Clearing amyloid through the blood-brain barrier
J Neurochem
2004
89
807
811

15140180


5.
Nagele
RG

D’Andrea
MR

Lee
H

Venkataraman
V

Wang
HY


Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains
Brain Res
2003
971
197
209

12706236


6.
Paresce
DM

Ghosh
RN

Maxfield
FR


Microglial cells internalize aggregates of the Alzheimer’s disease amyloid beta-protein via a scavenger receptor
Neuron
1996
17
553
565

8816718


7.
Tanzi
RE

Moir
RD

Wagner
SL


Clearance of Alzheimer’s Abeta peptide: the many roads to perdition
Neuron
2004
43
605
608

15339642


8.
Selkoe
DJ


Alzheimer’s disease: genotypes, phenotypes, and treatments
Science
1997
275
630
631

9019820


9.
Selkoe
DJ


The origins of Alzheimer disease: a is for amyloid
JAMA
2000
283
1615
1617

10735401


10.
Deane
R

Wu
Z

Sagare
A

Davis
J

Du
YS

Hamm
K

Xu
F

Parisi
M

LaRue
B

Hu
HW

Spijkers
P

Guo
H

Song
X

Lenting
PJ

Nostrand
WE

Zlokovic
BV


LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms
Neuron
2004
43
333
344

15294142


11.
Dickson
DW


The pathogenesis of senile plaques
J Neuropathol ExpNeurol
1997
56
321
339

Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol ExpNeurol 56:321–339 

12.
Rogers
J

Cooper
NR

Webster
S

Schultz
J

McGeer
PL

Styren
SD

Civin
WH

Brachova
L

Bradt
B

Ward
P


Complement activation by beta-amyloid in Alzheimer disease
Proc Natl Acad Sci USA
1992
89
10016
10020

1438191


13.
Rogers
J

Lue
LF


Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer’s disease
Neurochem Int
2001
39
333
340

11578768


14.
Boyles
JK

Pitas
RE

Wilson
E

Mahley
RW

Taylor
JM


Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system
J Clin Invest
1985
76
1501
1513

3932467


15.
Pitas
RE

Boyles
JK

Lee
SH

Foss
D

Mahley
RW


Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Biochim Biophys Acta
1987
917
148
161

3539206


16.
Pitas
RE

Boyles
JK

Lee
SH

Hui
D

Weisgraber
KH


Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain
J Biol Chem
1987
262
14352
14360

3115992


17.
Stone
DJ

Rozovsky
I

Morgan
TE

Anderson
CP

Hajian
H

Finch
CE


Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro
Exp Neurol
1997
143
313
318

9056393


18.
Wilhelmus
MM

Otte-Holler
I

Davis
J

Nostrand
WE

Waal
RM

Verbeek
MM


Apolipoprotein E genotype regulates amyloid-beta cytotoxicity
J Neurosci
2005
25
3621
3627

15814793


19.
Mahley
RW


Apolipoprotein E: cholesterol transport protein with expanding role in cell biology
Science
1988
240
622
630

3283935


20.
Plump
AS

Breslow
JL


Apolipoprotein E and the apolipoprotein E-deficient mouse
Annu Rev Nutr
1995
15
495
518

8527231


21.
Corder
EH

Saunders
AM

Strittmatter
WJ

Schmechel
DE

Gaskell
PC

Small
GW

Roses
AD

Haines
JL

Pericak-Vance
MA


Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families
Science
1993
261
921
923

8346443


22.
Corder
EH

Saunders
AM

Risch
NJ

Strittmatter
WJ

Schmechel
DE

Gaskell
PC

Rimmler
JB

Locke
PA

Conneally
PM

Schmader
KE


Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Nat Genet
1994
7
180
184

7920638


23.
Mayeux
R

Stern
Y

Ottman
R

Tatemichi
TK

Tang
MX

Maestre
G

Ngai
C

Tycko
B

Ginsberg
H


The apolipoprotein epsilon 4 allele in patients with Alzheimer’s disease
Ann Neurol
1993
34
752
754

8239575


24.
Strittmatter
WJ

Roses
AD


Apolipoprotein E and Alzheimer’s disease
Annu Rev Neurosci
1996
19
53
77

8833436


25.
Namba
Y

Tomonaga
M

Kawasaki
H

Otomo
E

Ikeda
K


Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt–Jakob disease
Brain Res
1991
541
163
166

2029618


26.
Wisniewski
T

Frangione
B


Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Neurosci Lett
1992
135
235
238

1625800


27.
Strittmatter
WJ

Saunders
AM

Schmechel
D

Pericak-Vance
M

Enghild
J

Salvesen
GS

Roses
AD


Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
Proc Natl Acad Sci USA
1993
90
1977
1981

8446617


28.
Strittmatter
WJ

Weisgraber
KH

Huang
DY

Dong
LM

Salvesen
GS

Pericak-Vance
M

Schmechel
D

Saunders
AM

Goldgaber
D

Roses
AD


Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease
Proc Natl Acad Sci USA
1993
90
8098
8102

8367470


29.
LaDu
MJ

Falduto
MT

Manelli
AM

Reardon
CA

Getz
GS

Frail
DE


Isoform-specific binding of apolipoprotein E to beta-amyloid
J Biol Chem
1994
269
23403
23406

8089103


30.
Strittmatter
WJ

Weisgraber
KH

Huang
DY

Dong
LM

Salvesen
GS

Pericak-Vance
M

Schmechel
D

Saunders
AM

Goldgaber
D

Roses
AD


Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease
Proc Natl Acad Sci USA
1993
90
8098
8102

8367470


31.
Bales
KR

Verina
T

Dodel
RC

Du
Y

Altstiel
L

Bender
M

Hyslop
P

Johnstone
EM

Little
SP

Cummins
DJ

Piccardo
P

Ghetti
B

Paul
SM


Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition
Nat Genet
1997
17
263
264

9354781


32.
Bales
KR

Verina
T

Cummins
DJ

Du
Y

Dodel
RC

Saura
J

Fishman
CE

DeLong
CA

Piccardo
P

Petegnief
V

Ghetti
B

Paul
SM


Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease
Proc Natl Acad Sci USA
1999
96
15233
15238

10611368


33.
Dolev
I

Michaelson
DM


A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade
Proc Natl Acad Sci USA
2004
101
13909
13914

15365176


34.
Fryer
JD

Taylor
JW

DeMattos
RB

Bales
KR

Paul
SM

Parsadanian
M

Holtzman
DM


Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice
J Neurosci
2003
23
7889
7896

12944519


35.
Sadowski
M

Pankiewicz
J

Scholtzova
H

Ripellino
JA

Li
Y

Schmidt
SD

Mathews
PM

Fryer
JD

Holtzman
DM

Sigurdsson
EM

Wisniewski
T


A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice
Am J Pathol
2004
165
937
948

15331417


36.
Holtzman
DM

Bales
KR

Wu
S

Bhat
P

Parsadanian
M

Fagan
AM

Chang
LK

Sun
Y

Paul
SM


Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease
J Clin Invest
1999
103
R15
R21

10079115


37.
Holtzman
DM

Bales
KR

Tenkova
T

Fagan
AM

Parsadanian
M

Sartorius
LJ

Mackey
B

Olney
J

McKeel
D

Wozniak
D

Paul
SM


Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease
Proc Natl Acad Sci USA
2000
97
2892
2897

10694577


38.
Carter
DB

Dunn
E

McKinley
DD

Stratman
NC

Boyle
TP

Kuiper
SL

Oostveen
JA

Weaver
RJ

Boller
JA

Gurney
ME


Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain
Ann Neurol
2001
50
468
475

11601499


39.
Fryer
JD

DeMattos
RB

McCormick
LM

O’Dell
MA

Spinner
ML

Bales
KR

Paul
SM

Sullivan
PM

Parsadanian
M

Bu
G

Holtzman
DM


The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice
J Biol Chem
2005
280
25754
25759

15888448


40.
Koistinaho
M

Lin
S

Wu
X

Esterman
M

Koger
D

Hanson
J

Higgs
R

Liu
F

Malkani
S

Bales
KR

Paul
SM


Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides
Nat Med
2004
10
719
726

15195085


41.
Strittmatter
WJ

Weisgraber
KH

Goedert
M

Saunders
AM

Huang
D

Corder
EH

Dong
LM

Jakes
R

Alberts
MJ

Gilbert
JR


Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype
Exp Neurol
1994
125
163
171

8313935


42.
Strittmatter
WJ

Saunders
AM

Goedert
M

Weisgraber
KH

Dong
LM

Jakes
R

Huang
DY

Pericak-Vance
M

Schmechel
D

Roses
AD


Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease
Proc Natl Acad Sci USA
1994
91
11183
11186

7972031


43.
Ghebremedhin
E

Schultz
C

Braak
E

Braak
H


High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer’s disease-related neurofibrillary changes
Exp Neurol
1998
153
152
155

9743577


44.
Ohm
TG

Scharnagl
H

Marz
W

Bohl
J


Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions
Acta Neuropathol (Berl)
1999
98
273
280

10483785


45.
Tesseur
I

Dorpe
J

Spittaels
K

den
HC

Moechars
D

Leuven
F


Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice
Am J Pathol
2000
156
951
964

10702411


46.
Yasojima
K

Schwab
C

McGeer
EG

McGeer
PL


Up-regulated production and activation of the complement system in Alzheimer’s disease brain
Am J Pathol
1999
154
927
936

10079271


47.
Barger
SW

Harmon
AD


Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
Nature
1997
388
878
881

9278049


48.
Hu
J

LaDu
MJ

Eldik
LJ


Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation
J Neurochem
1998
71
1626
1634

9751196


49.
Laskowitz
DT

Goel
S

Bennett
ER

Matthew
WD


Apolipoprotein E suppresses glial cell secretion of TNF alpha
J Neuroimmunol
1997
76
70
74

9184634


50.
Laskowitz
DT

Lee
DM

Schmechel
D

Staats
HF


Altered immune responses in apolipoprotein E-deficient mice
J Lipid Res
2000
41
613
620

10744782


51.
Lynch
JR

Morgan
D

Mance
J

Matthew
WD

Laskowitz
DT


Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response
J Neuroimmunol
2001
114
107
113

11240021


52.
Colton
CA

Brown
CM

Czapiga
M

Vitek
MP


Apolipoprotein-E allele-specific regulation of nitric oxide production
Ann N Y Acad Sci
2002
962
212
225

12076977


53.
Trougakos
IP

Gonos
ES


Clusterin/apolipoprotein J in human aging and cancer
Int J Biochem Cell Biol
2002
34
1430
1448

12200037


54.
Calero
M

Rostagno
A

Matsubara
E

Zlokovic
B

Frangione
B

Ghiso
J


Apolipoprotein J (clusterin) and Alzheimer’s disease
Microsc Res Tech
2000
50
305
315

10936885


55.
Rosenberg
ME

Dvergsten
J

Correa-Rotter
R


Clusterin: an enigmatic protein recruited by diverse stimuli
J Lab Clin Med
1993
121
205
214

8433037


56.
Zlokovic
BV

Martel
CL

Mackic
JB

Matsubara
E

Wisniewski
T

McComb
JG

Frangione
B

Ghiso
J


Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer’s amyloid beta
Biochem Biophys Res Commun
1994
205
1431
1437

7802679


57.
Rassart
E

Bedirian
A

Do
CS

Guinard
O

Sirois
J

Terrisse
L

Milne
R


Apolipoprotein D
Biochim Biophys Acta
2000
1482
185
198

11058760


58.
Belloir
B

Kovari
E

Surini-Demiri
M

Savioz
A


Altered apolipoprotein D expression in the brain of patients with Alzheimer disease
J Neurosci Res
2001
64
61
69

11276052


59.
Terrisse
L

Seguin
D

Bertrand
P

Poirier
J

Milne
R

Rassart
E


Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion
Brain Res Mol Brain Res
1999
70
26
35

10381540


60.
Bernfield
M

Gotte
M

Park
PW

Reizes
O

Fitzgerald
ML

Lincecum
J

Zako
M


Functions of cell surface heparan sulfate proteoglycans
Annu Rev Biochem
1999
68
729
777

10872465


61.
Horssen
J

Wesseling
P

Heuvel
LP

Waal
RM

Verbeek
MM


Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-related disorders
Lancet Neurol
2003
2
482
492

12878436


62.
Iozzo
RV


Heparan sulfate proteoglycans: intricate molecules with intriguing functions
J Clin Invest
2001
108
165
167

11457866


63.
Perry
G

Siedlak
SL

Richey
P

Kawai
M

Cras
P

Kalaria
RN

Galloway
PG

Scardina
JM

Cordell
B

Greenberg
BD


Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer’s disease
J Neurosci
1991
11
3679
3683

1941102


64.
Snow
AD

Mar
H

Nochlin
D

Kimata
K

Kato
M

Suzuki
S

Hassell
J

Wight
TN


The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer’s disease
Am J Pathol
1988
133
456
463

2974240


65.
Snow
AD

Mar
H

Nochlin
D

Sekiguchi
RT

Kimata
K

Koike
Y

Wight
TN


Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer’s disease and Down’s syndrome
Am J Pathol
1990
137
1253
1270

2146882


66.
Snow
AD

Sekiguchi
RT

Nochlin
D

Kalaria
RN

Kimata
K


Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer’s disease brain
Am J Pathol
1994
144
337
347

8311117


67.
Snow
AD

Kinsella
MG

Parks
E

Sekiguchi
RT

Miller
JD

Kimata
K

Wight
TN


Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer’s disease
Arch Biochem Biophys
1995
320
84
95

7793988


68.
Horssen
J

Otte-Holler
I

David
G

Maat-Schieman
ML

Heuvel
LP

Wesseling
P

Waal
RM

Verbeek
MM


Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer’s disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains
Acta Neuropathol (Berl)
2001
102
604
614

11761721


69.
Verbeek
MM

Otte-Holler
I

den
BJ

Heuvel
LP

David
G

Wesseling
P

Waal
RM


Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer’s disease brain
Am J Pathol
1999
155
2115
2125

10595940


70.
Cotman
SL

Halfter
W

Cole
GJ


Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer’s disease brain
Mol Cell Neurosci
2000
15
183
198

10673326


71.
Donahue
JE

Berzin
TM

Rafii
MS

Glass
DJ

Yancopoulos
GD

Fallon
JR

Stopa
EG


Agrin in Alzheimer’s disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma
Proc Natl Acad Sci USA
1999
96
6468
6472

10339611


72.
Horssen
J

Wilhelmus
MM

Heljasvaara
R

Pihlajaniemi
T

Wesseling
P

Waal
RM

Verbeek
MM


Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer’s disease brains
Brain Pathol
2002
12
456
462

12408231


73.
Gupta-Bansal
R

Frederickson
RC

Brunden
KR


Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation
J Biol Chem
1995
270
18666
18671

7629198


74.
Castillo
GM

Ngo
C

Cummings
J

Wight
TN

Snow
AD


Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer’s disease, accelerates A beta fibril formation, and maintains A beta fibril stability
J Neurochem
1997
69
2452
2465

9375678


75.
Snow
AD

Sekiguchi
R

Nochlin
D

Fraser
P

Kimata
K

Mizutani
A

Arai
M

Schreier
WA

Morgan
DG


An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain
Neuron
1994
12
219
234

8292358


76.
Verbeek
MM

Eikelenboom
P

Waal
RM


Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease
J Neuropathol Exp Neurol
1997
56
751
761

9210871


77.
Buee
L

Ding
W

Anderson
JP

Narindrasorasak
S

Kisilevsky
R

Boyle
NJ

Robakis
NK

Delacourte
A

Greenberg
B

Fillit
HM


Binding of vascular heparan sulfate proteoglycan to Alzheimer’s amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide
Brain Res
1993
627
199
204

8298962


78.
Narindrasorasak
S

Lowery
D

Gonzalez-DeWhitt
P

Poorman
RA

Greenberg
B

Kisilevsky
R


High affinity interactions between the Alzheimer’s beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan
J Biol Chem
1991
266
12878
12883

1906461


79.
Snow
AD

Willmer
JP

Kisilevsky
R


Sulfated glycosaminoglycans in Alzheimer’s disease
Hum Pathol
1987
18
506
510

3570282


80.
Goedert
M

Jakes
R

Spillantini
MG

Hasegawa
M

Smith
MJ

Crowther
RA


Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans
Nature
1996
383
550
553

8849730


81.
Gervais
F

Chalifour
R

Garceau
D

Kong
X

Laurin
J

Mclaughlin
R

Morissette
C

Paquette
J


Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy
Amyloid
2001
8
Suppl 1
28
35

11676287


82.
Zhu
H

Yu
J

Kindy
MS


Inhibition of amyloidosis using low-molecular-weight heparins
Mol Med
2001
7
517
522

11591887


83.
Kisilevsky
R

Lemieux
LJ

Fraser
PE

Kong
X

Hultin
PG

Szarek
WA


Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer’s disease
Nat Med
1995
1
143
148

7585011


84.
Banz
Y

Hess
OM

Robson
SC

Mettler
D

Meier
P

Haeberli
A

Csizmadia
E

Korchagina
EY

Bovin
NV

Rieben
R


Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury
Eur Heart J
2005
26
2334
2343

16055495


85.
Kirschfink
M

Blase
L

Engelmann
S

Schwartz-Albiez
R


Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1
J Immunol
1997
158
1324
1331

9013976


86.
Caughman
GB

Boackle
RJ

Vesely
J


A postulated mechanism for heparin’s potentiation of C1 inhibitor function
Mol Immunol
1982
19
287
295

7099168


87.
Eikelenboom
P

Stam
FC


Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study
Acta Neuropathol (Berl)
1982
57
239
242

6812382


88.
Eikelenboom
P

Stam
FC


An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer’s dementia
Virchows Arch B Cell Pathol Incl Mol Pathol
1984
47
17
25

6151285


89.
McGeer
PL

Akiyama
H

Itagaki
S

McGeer
EG


Activation of the classical complement pathway in brain tissue of Alzheimer patients
Neurosci Lett
1989
107
341
346

2559373


90.
Webster
S

Bradt
B

Rogers
J

Cooper
N


Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide
J Neurochem
1997
69
388
398

9202333


91.
Webster
S

Lue
LF

Brachova
L

Tenner
AJ

McGeer
PL

Terai
K

Walker
DG

Bradt
B

Cooper
NR

Rogers
J


Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease
Neurobiol Aging
1997
18
415
421

9330973


92.
Yasuhara
O

Walker
DG

McGeer
PL


Hageman factor and its binding sites are present in senile plaques of Alzheimer’s disease
Brain Res
1994
654
234
240

7987673


93.
Rozemuller
AJ

Eikelenboom
P

Theeuwes
JW

Jansen Steur
EN

Vos
RA


Activated microglial cells and complement factors are unrelated to cortical Lewy bodies
Acta Neuropathol (Berl)
2000
100
701
708

11078223


94.
Chen
S

Frederickson
RC

Brunden
KR


Neuroglial-mediated immunoinflammatory responses in Alzheimer’s disease: complement activation and therapeutic approaches
Neurobiol Aging
1996
17
781
787

8892352


95.
Veerhuis
R

Janssen
I

Hoozemans
JJ

Groot
CJ

Hack
CE

Eikelenboom
P


Complement C1-inhibitor expression in Alzheimer’s disease
Acta Neuropathol (Berl)
1998
96
287
296

9754962


96.
Walker
DG

Yasuhara
O

Patston
PA

McGeer
EG

McGeer
PL


Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease
Brain Res
1995
675
75
82

7796155


97.
Wyss-Coray
T

Yan
F

Lin
AH

Lambris
JD

Alexander
JJ

Quigg
RJ

Masliah
E


Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice
Proc Natl Acad Sci USA
2002
99
10837
10842

12119423


98.
Abraham
CR


Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer’s disease
Neurobiol Aging
2001
22
931
936

11755001


99.
Gasque
P

Dean
YD

McGreal
EP

VanBeek
J

Morgan
BP


Complement components of the innate immune system in health and disease in the CNS
Immunopharmacology
2000
49
171
186

10904116


100.
Wyss-Coray
T

Mucke
L


Inflammation in neurodegenerative disease—a double-edged sword
Neuron
2002
35
419
432

12165466


101.
Jiang
H

Burdick
D

Glabe
CG

Cotman
CW

Tenner
AJ


Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain
J Immunol
1994
152
5050
5059

8176223


102.
Webster
S

Bonnell
B

Rogers
J


Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide
Am J Pathol
1997
150
1531
1536

9137079


103.
Bitting
L

Naidu
A

Cordell
B

Murphy
GM


Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide
J Biol Chem
1996
271
16084
16089

8663228


104.
Veerhuis
R

Breemen
MJ

Hoozemans
JM

Morbin
M

Ouladhadj
J

Tagliavini
F

Eikelenboom
P


Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro
Acta Neuropathol (Berl)
2003
105
135
144

12536224


105.
Walter
S

Buchner
J


Molecular chaperones—cellular machines for protein folding
Angew Chem Int Ed Engl
2002
41
1098
1113

12491239


106.
Gusev
NB

Bogatcheva
NV

Marston
SB


Structure and properties of small heat shock proteins (sHsp) and their interaction with cytoskeleton proteins
Biochemistry (Mosc)
2002
67
511
519

12059769


107.
MacRae
TH


Structure and function of small heat shock/alpha-crystallin proteins: established concepts and emerging ideas
Cell Mol Life Sci
2000
57
899
913

10950306


108.
Buchner
J


Supervising the fold: functional principles of molecular chaperones
FASEB J
1996
10
10
19

8566529


109.
Jong
WW

Caspers
GJ

Leunissen
JA


Genealogy of the alpha-crystallin–small heat-shock protein superfamily
Int J Biol Macromol
1998
22
151
162

9650070


110.
Kappe
G

Franck
E

Verschuure
P

Boelens
WC

Leunissen
JA

Jong
WW


The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10
Cell Stress Chaperones
2003
8
53
61

12820654


111.
Iwaki
T

Wisniewski
T

Iwaki
A

Corbin
E

Tomokane
N

Tateishi
J

Goldman
JE


Accumulation of alpha B-crystallin in central nervous system glia and neurons in pathologic conditions
Am J Pathol
1992
140
345
356

1739128


112.
Renkawek
K

Voorter
CE

Bosman
GJ

Workum
FP

Jong
WW


Expression of alpha B-crystallin in Alzheimer’s disease
Acta Neuropathol (Berl)
1994
87
155
160

8171966


113.
Renkawek
K

Bosman
GJ

Jong
WW


Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia
Acta Neuropathol (Berl)
1994
87
511
519

8059604


114.
Shinohara
H

Inaguma
Y

Goto
S

Inagaki
T

Kato
K


Alpha B crystallin and HSP28 are enhanced in the cerebral cortex of patients with Alzheimer’s disease
J Neurol Sci
1993
119
203
208

8277336


115.
Wilhelmus
MM

Otte-Holler
I

Wesseling
P

Waal
RM

Boelens
WC

Verbeek
MM


Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer’s disease brains
Neuropathol Appl Neurobiol
2006
32
119
130

16599941


116.
Wilhelmus
MM

Boelens
WC

Otte-Holler
I

Kamps
B

Kusters
B

Maat-Schieman
ML

Waal
RM

Verbeek
MM


Small heat shock protein HspB8: its distribution in Alzheimer’s disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity
Acta Neuropathol (Berl)
2006
111
139
149

16485107


117.
Wilhelmus
MM

Boelens
WC

Otte-Holler
I

Kamps
B

Waal
RM

Verbeek
MM


Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity
Brain Res
2006
1089
67
78

16635482


118.
Kudva
YC

Hiddinga
HJ

Butler
PC

Mueske
CS

Eberhardt
NL


Small heat shock proteins inhibit in vitro A beta(1-42) amyloidogenesis
FEBS Lett
1997
416
117
121

9369246


119.
Liang
JJ


Interaction between beta-amyloid and lens alphaB-crystallin
FEBS Lett
2000
484
98
101

11068040


120.
Goldstein
LE

Muffat
JA

Cherny
RA

Moir
RD

Ericsson
MH

Huang
X

Mavros
C

Coccia
JA

Faget
KY

Fitch
KA

Masters
CL

Tanzi
RE

Chylack
LT

Bush
AI


Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease
Lancet
2003
361
1258
1265

12699953


121.
Stege
GJ

Renkawek
K

Overkamp
PS

Verschuure
P

Rijk
AF

Reijnen-Aalbers
A

Boelens
WC

Bosman
GJ

Jong
WW


The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity
Biochem Biophys Res Commun
1999
262
152
156

10448084


122.
Shimura
H

Miura-Shimura
Y

Kosik
KS


Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival
J Biol Chem
2004
279
17957
17962

14963027


123.
Auluck
PK

Chan
HY

Trojanowski
JQ

Lee
VM

Bonini
NM


Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease
Science
2002
295
865
868

11823645


124.
McLean
PJ

Kawamata
H

Shariff
S

Hewett
J

Sharma
N

Ueda
K

Breakefield
XO

Hyman
BT


TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation
J Neurochem
2002
83
846
854

12421356


125.
Renkawek
K

Jong
WW

Merck
KB

Frenken
CW

Workum
FP

Bosman
GJ


alpha B-crystallin is present in reactive glia in Creutzfeldt–Jakob disease
Acta Neuropathol (Berl)
1992
83
324
327

1373027


126.
Renkawek
K

Bosman
GJ

Gaestel
M


Increased expression of heat-shock protein 27 kDa in Alzheimer disease: a preliminary study
Neuroreport
1993
5
14
16

8280851


127.
Nardai
G

Csermely
P

Soti
C


Chaperone function and chaperone overload in the aged. A preliminary analysis
Exp Gerontol
2002
37
1257
1262

12470839


128.
Csermely
P


Chaperone overload is a possible contributor to ‘civilization diseases’
Trends Genet
2001
17
701
704

11718923


129.
Abraham
CR

Shirahama
T

Potter
H


Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin
Neurobiol Aging
1990
11
123
129

2190106


130.
Bauer
J

Strauss
S

Schreiter-Gasser
U

Ganter
U

Schlegel
P

Witt
I

Yolk
B

Berger
M


Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices
FEBS Lett
1991
285
111
114

1712317


131.
Holm
NE

Nybo
M

Junker
K

Toftedal
HP

Rasmussen
IM

Svehag
SE


Localization of human serum amyloid P component and heparan sulfate proteoglycan in in vitro-formed Abeta fibrils
Scand J Immunol
2000
52
110
112

10931376


132.
Prohaszka
Z

Singh
M

Nagy
K

Kiss
E

Lakos
G

Duba
J

Fust
G


Heat shock protein 70 is a potent activator of the human complement system
Cell Stress Chaperones
2002
7
17
22

11892984


133.
Licastro
F

Mallory
M

Hansen
LA

Masliah
E


Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer’s disease correlate with activated astrocytes and are affected by APOE 4 genotype
J Neuroimmunol
1998
88
105
110

9688331


134.
Eriksson
S

Janciauskiene
S

Lannfelt
L


Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation
Proc Natl Acad Sci USA
1995
92
2313
2317

7892264


135.
Ma
J

Yee
A

Brewer
HB

Das
S

Potter
H


Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments
Nature
1994
372
92
94

7969426


136.
Du
Y

Bales
KR

Dodel
RC

Liu
X

Glinn
MA

Horn
JW

Little
SP

Paul
SM


Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons
J Neurochem
1998
70
1182
1188

9489740


137.
Hughes
SR

Khorkova
O

Goyal
S

Knaeblein
J

Heroux
J

Riedel
NG

Sahasrabudhe
S


Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation
Proc Natl Acad Sci USA
1998
95
3275
3280

9501253


138.
Lauer
D

Reichenbach
A

Birkenmeier
G


Alpha 2-macroglobulin-mediated degradation of amyloid beta 1–42: a mechanism to enhance amyloid beta catabolism
Exp Neurol
2001
167
385
392

11161627


139.
Narita
M

Holtzman
DM

Schwartz
AL

Bu
G


Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein
J Neurochem
1997
69
1904
1911

9349534


140.
Emsley
J

White
HE

O’Hara
BP

Oliva
G

Srinivasan
N

Tickle
IJ

Blundell
TL

Pepys
MB

Wood
SP


Structure of pentameric human serum amyloid P component
Nature
1994
367
338
345

8114934


141.
McGeer
EG

Yasojima
K

Schwab
C

McGeer
PL


The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases
Neurobiol Aging
2001
22
843
848

11754991


142.
Ying
SC

Gewurz
AT

Jiang
H

Gewurz
H


Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q
J Immunol
1993
150
169
176

8417122


143.
Sappino
AP

Madani
R

Huarte
J

Belin
D

Kiss
JZ

Wohlwend
A

Vassalli
JD


Extracellular proteolysis in the adult murine brain
J Clin Invest
1993
92
679
685

8349806


144.
Kingston
IB

Castro
MJ

Anderson
S


In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues
Nat Med
1995
1
138
142

7585010


145.
Tucker
HM

Kihiko-Ehmann
M

Wright
S

Rydel
RE

Estus
S


Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition
J Neurochem
2000
75
2172
2177

11032907


146.
Melchor
JP

Pawlak
R

Strickland
S


The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration
J Neurosci
2003
23
8867
8871

14523088


147.
Kwiatkowski
DJ

Stossel
TP

Orkin
SH

Mole
JE

Colten
HR

Yin
HL


Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain
Nature
1986
323
455
458

3020431


148.
Kwiatkowski
DJ

Mehl
R

Yin
HL


Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin
J Cell Biol
1988
106
375
384

2828382


149.
Chauhan
VP

Ray
I

Chauhan
A

Wisniewski
HM


Binding of gelsolin, a secretory protein, to amyloid beta-protein
Biochem Biophys Res Commun
1999
258
241
246

10329371


150.
Ray
I

Chauhan
A

Wegiel
J

Chauhan
VP


Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils
Brain Res
2000
853
344
351

10640633


151.
Qiao
H

Koya
RC

Nakagawa
K

Tanaka
H

Fujita
H

Takimoto
M

Kuzumaki
N


Inhibition of Alzheimer’s amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin
Neurobiol Aging
2005
26
849
855

15718043


152.
Naiki
H

Nakakuki
K


First-order kinetic model of Alzheimer’s beta-amyloid fibril extension in vitro
Lab Invest
1996
74
374
383

8780157


153.
Hayashi
H

Kimura
N

Yamaguchi
H

Hasegawa
K

Yokoseki
T

Shibata
M

Yamamoto
N

Michikawa
M

Yoshikawa
Y

Terao
K

Matsuzaki
K

Lemere
CA

Selkoe
DJ

Naiki
H

Yanagisawa
K


A seed for Alzheimer amyloid in the brain
J Neurosci
2004
24
4894
4902

15152051


154.
Kakio
A

Nishimoto
SI

Yanagisawa
K

Kozutsumi
Y

Matsuzaki
K


Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid
J Biol Chem
2001
276
24985
24990

11342534


155.
Kawarabayashi
T

Shoji
M

Younkin
LH

Wen-Lang
L

Dickson
DW

Murakami
T

Matsubara
E

Abe
K

Ashe
KH

Younkin
SG


Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer’s disease
J Neurosci
2004
24
3801
3809

15084661


156.
Parton
RG


Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae
J Histochem Cytochem
1994
42
155
166

8288861


157.
Greenfield
JP

Tsai
J

Gouras
GK

Hai
B

Thinakaran
G

Checler
F

Sisodia
SS

Greengard
P

Xu
H


Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides
Proc Natl Acad Sci USA
1999
96
742
747

9892704


158.
Hartmann
T

Bieger
SC

Bruhl
B

Tienari
PJ

Ida
N

Allsop
D

Roberts
GW

Masters
CL

Dotti
CG

Unsicker
K

Beyreuther
K


Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides
Nat Med
1997
3
1016
1020

9288729


159.
Xu
H

Sweeney
D

Wang
R

Thinakaran
G

Lo
AC

Sisodia
SS

Greengard
P

Gandy
S


Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation
Proc Natl Acad Sci USA
1997
94
3748
3752

9108049


160.
Gouras
GK

Tsai
J

Naslund
J

Vincent
B

Edgar
M

Checler
F

Greenfield
JP

Haroutunian
V

Buxbaum
JD

Xu
H

Greengard
P

Relkin
NR


Intraneuronal Abeta42 accumulation in human brain
Am J Pathol
2000
156
15
20

10623648


161.
LaFerla
FM

Troncoso
JC

Strickland
DK

Kawas
CH

Jay
G


Neuronal cell death in Alzheimer’s disease correlates with apoE uptake and intracellular Abeta stabilization
J Clin Invest
1997
100
310
320

9218507


162.
Oddo
S

Caccamo
A

Shepherd
JD

Murphy
MP

Golde
TE

Kayed
R

Metherate
R

Mattson
MP

Akbari
Y

LaFerla
FM


Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction
Neuron
2003
39
409
421

12895417


163.
Yan
SD

Fu
J

Soto
C

Chen
X

Zhu
H

Al Mohanna
F

Collison
K

Zhu
A

Stern
E

Saido
T

Tohyama
M

Ogawa
S

Roher
A

Stern
D


An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer’s disease
Nature
1997
389
689
695

9338779


164.
Yan
SD

Stern
DM


Mitochondrial dysfunction and Alzheimer’s disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD)
Int J Exp Pathol
2005
86
161
171

15910550


165.
Yang
Y

Turner
RS

Gaut
JR


The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Abeta40 and Abeta42 secretion
J Biol Chem
1998
273
25552
25555

9748217


166.
Fonte
V

Kapulkin
V

Taft
A

Fluet
A

Friedman
D

Link
CD


Interaction of intracellular beta amyloid peptide with chaperone proteins
Proc Natl Acad Sci USA
2002
99
9439
9444

12089340


167.
Magrane
J

Smith
RC

Walsh
K

Querfurth
HW


Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons
J Neurosci
2004
24
1700
1706

14973234


168.
Perez
N

Sugar
J

Charya
S

Johnson
G

Merril
C

Bierer
L

Perl
D

Haroutunian
V

Wallace
W


Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer’s disease
Brain Res Mol Brain Res
1991
11
249
254

1661822


169.
Hamos
JE

Oblas
B

Pulaski-Salo
D

Welch
WJ

Bole
DG

Drachman
DA


Expression of heat shock proteins in Alzheimer’s disease
Neurology
1991
41
345
350

2005999


170.
Kitamura
Y

Nomura
Y


Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders
Pharmacol Ther
2003
97
35
53

12493534


171.
Anthony
SG

Schipper
HM

Tavares
R

Hovanesian
V

Cortez
SC

Stopa
EG

Johanson
CE


Stress protein expression in the Alzheimer-diseased choroid plexus
J Alzheimers Dis
2003
5
171
177

12897402


172.
Dou
F

Netzer
WJ

Tanemura
K

Li
F

Hartl
FU

Takashima
A

Gouras
GK

Greengard
P

Xu
H


Chaperones increase association of tau protein with microtubules
Proc Natl Acad Sci USA
2003
100
721
726

12522269


173.
Shimura
H

Schwartz
D

Gygi
SP

Kosik
KS


CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival
J Biol Chem
2004
279
4869
4876

14612456


174.
Schuller
E

Gulesserian
T

Seidl
R

Cairns
N

Lube
G


Brain t-complex polypeptide 1 (TCP-1) related to its natural substrate beta1 tubulin is decreased in Alzheimer’s disease
Life Sci
2001
69
263
270

11441917


175.
Shibata
M

Yamada
S

Kumar
SR

Calero
M

Bading
J

Frangione
B

Holtzman
DM

Miller
CA

Strickland
DK

Ghiso
J

Zlokovic
BV


Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier
J Clin Invest
2000
106
1489
1499

11120756


176.
Deane
R

Du
YS

Submamaryan
RK

LaRue
B

Jovanovic
S

Hogg
E

Welch
D

Manness
L

Lin
C

Yu
J

Zhu
H

Ghiso
J

Frangione
B

Stern
A

Schmidt
AM

Armstrong
DL

Arnold
B

Liliensiek
B

Nawroth
P

Hofman
F

Kindy
M

Stern
D

Zlokovic
B


RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain
Nat Med
2003
9
907
913

12808450


177.
Mackic
JB

Stins
M

McComb
JG

Calero
M

Ghiso
J

Kim
KS

Yan
SD

Stern
D

Schmidt
AM

Frangione
B

Zlokovic
BV


Human blood–brain barrier receptors for Alzheimer’s amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer
J Clin Invest
1998
102
734
743

9710442


178.
Zlokovic
BV


Neurovascular mechanisms of Alzheimer’s neurodegeneration
Trends Neurosci
2005
28
202
208

15808355


179.
Ruiz
J

Kouiavskaia
D

Migliorini
M

Robinson
S

Saenko
EL

Gorlatova
N

Li
D

Lawrence
D

Hyman
BT

Weisgraber
KH

Strickland
DK


The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor
J Lipid Res
2005
46
1721
1731

15863833


180.
DeMattos
RB

Bales
KR

Cummins
DJ

Dodart
JC

Paul
SM

Holtzman
DM


Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease
Proc Natl Acad Sci USA
2001
98
8850
8855

11438712


181.
DeMattos
RB

Bales
KR

Cummins
DJ

Paul
SM

Holtzman
DM


Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease
Science
2002
295
2264
2267

11910111


182.
Bacskai
BJ

Kajdasz
ST

McLellan
ME

Games
D

Seubert
P

Schenk
D

Hyman
BT


Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy
J Neurosci
2002
22
7873
7878

12223540


183.
Hock
C

Konietzko
U

Streffer
JR

Tracy
J

Signorell
A

Muller-Tillmanns
B

Lemke
U

Henke
K

Moritz
E

Garcia
E

Wollmer
MA

Umbricht
D

Quervain
DJ

Hofmann
M

Maddalena
A

Papassotiropoulos
A

Nitsch
RM


Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease
Neuron
2003
38
547
554

12765607


184.
Matsuoka
Y.

Saito
M.

LaFrancois
J.

Saito
M.

Gaynor
K.

Olm
V.

Wang
L.

Casey
E.

Lu
Y.

Shiratori
C.

Lemere
C.

Duff
K.


Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid
J Neurosci
2003
23
29
33

12514198


185.
Akiyama
H

Barger
S

Barnum
S

Bradt
B

Bauer
J

Cole
GM

Cooper
NR

Eikelenboom
P

Emmerling
M

Fiebich
BL

Finch
CE

Frautschy
S

Griffin
WS

Hampel
H

Hull
M

Landreth
G

Lue
L

Mrak
R

Mackenzie
IR

McGeer
PL

O’Banion
MK

Pachter
J

Pasinetti
G

Plata-Salaman
C

Rogers
J

Rydel
R

Shen
Y

Streit
W

Strohmeyer
R

Tooyoma
I

Muiswinkel
FL

Veerhuis
R

Walker
D

Webster
S

Wegrzyniak
B

Wenk
G

Wyss-Coray
T


Inflammation and Alzheimer’s disease
Neurobiol Aging
2000
21
383
421

10858586


186.
DeWitt
DA

Perry
G

Cohen
M

Doller
C

Silver
J


Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer’s disease
Exp Neurol
1998
149
329
340

9500964


187.
McGeer
PL

McGeer
EG


The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
Brain Res Brain Res Rev
1995
21
195
218

8866675


188.
Kakimura
J

Kitamura
Y

Taniguchi
T

Shimohama
S

Gebicke-Haerter
PJ


Bip/GRP78-induced production of cytokines and uptake of amyloid-beta(1-42) peptide in microglia
Biochem Biophys Res Commun
2001
281
6
10

11178952


189.
Kakimura
J

Kitamura
Y

Takata
K

Umeki
M

Suzuki
S

Shibagaki
K

Taniguchi
T

Nomura
Y

Gebicke-Haerter
PJ

Smith
MA

Perry
G

Shimohama
S


Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins
FASEB J
2002
16
601
603

11919167





